News

SanAir Technologies Laboratory Combines with Centek Laboratories

Expands Lab Testing Capabilities into Volatile Organic Compound (VOC) Air and Soil Gas Analysis

RICHMOND, Va., SanAir Technologies Laboratory, Inc. (SanAir) today announced its merger with Syracuse, NY-based Centek Laboratories, LLC (Centek), expanding its testing capabilities into VOCs using summa cannister and/or thermal desorption tubes technology (EPA Method TO-15 and TO-17) and analyzation of samples by GC/MS coupled with cryo-focusing or thermal desorption technology.

“Like SanAir, Centek is in the environmental laboratory analysis business but with additional capabilities not currently covered by our lab,” said SanAir President Sean P. McGlynn. “Centek has been a leader in vapor intrusion technology since they opened their doors in 2003, when they helped New York State’s Department of Health and its Department of Environmental Conservation change how samples were collected and tested, improving the technology to save money and increase detection limits in the ppb (part per billion) and ppt (part per trillion) detection range. They have brought that innovative, client-focused spirit to LEED®, WELL, IgCC Certification System; Biogas, Industrial Hygiene and Product Testing. We are excited to have Centek under the SanAir umbrella.”

The combined laboratories represent a total of 70 employees in Virginia, Ohio and New York.

Centek has been working in green and sustainable technology through indoor air quality (IAQ) testing since 2009 in conjunction with the U.S. Green Building Counsel (USGBC). Current testing programs include: LEED® IEQ Credit 3.2 2009 for New Construction and Major Renovations; LEED V4; LEED 4.1; WELL; and IgCC. Centek has been doing this testing throughout the United States, Canada and Mexico and is starting to open doors overseas.

Centek also has been testing BioGas reclamation systems in landfills and wastewater treatment plants (WWTP) throughout North America. The lab identifies a complete gas profile and determines the proper treatment processes needed to meet even the most stringent biogas specifications for use as a fuel.

“We are excited about the opportunities presented by our merger with SanAir,” said Russell Pellegrino, Centek’s Technical Director. “Our companies are similarly entrepreneurial but also grounded in our foundational principles of scientific accuracy and reliability in testing.

SanAir’s resources will help Centek continue to innovate and bring cost and time-efficient sampling solutions to our clients.”

The combination of the two laboratories caps a year of expansion for SanAir that includes moving into a new headquarters location in Greater Richmond (North Chesterfield) at the former Virginia Department of Emergency Management location, and the first fully operational and accredited year of industrial hemp and medical marijuana testing for the Company’s wholly-owned subsidiary, Sativa Testing Laboratories.

Read more here.

Recent News

02/25/2026

Rivus Pharmaceuticals Appoints Jorge Bartolome as Chief Executive Officer

Rivus Pharmaceuticals Inc., a clinical-stage biopharmaceutical company dedicated to treating MASH, obesity, and associated cardiometabolic diseases, today announced the appointment of Jorge Bartolome as Chief Executive Officer and member of the Board. He succeeds Allen Cunningham, a co-founder who will move to the role of Chief Operating Officer. Mr. Bartolome has over 25 years of

02/24/2026

Jeeva Clinical Trials Calls on Global Life Sciences Leaders to Modernize Infrastructure for AI-Driven Drug Development

Jeeva Clinical Trials today amplified its call to action for the global pharmaceutical and clinical research ecosystem: Artificial Intelligence will not transform drug development unless organizations modernize the IT infrastructure beneath it. The message — first articulated in a recent thought leadership article by Founder and CEO Harsha K. Rajasimha — has gained strong traction

02/24/2026

Liquet™ Medical Receives Second FDA 510(k) Clearance for Versus™ Catheter

Liquet Medical Inc., a pioneering medical device company committed to advancing patient care through innovative technologies, today announced it has received a second 510(k) clearance from the U.S. Food and Drug Administration (FDA) for a new configuration of the Versus™ Catheter. The latest clearance expands the company’s proprietary platform and opens access to a broader